{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:07:07Z","timestamp":1774566427941,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-small cell lung cancer (NSCLC) with brain metastasis (BM) is associated with poor prognosis. For those patients with MET exon 14 skipping mutation (METex14), although MET tyrosine kinase inhibitors (MET TKIs) have emerged, but their efficacy remains limited, with the median progression-free survival (PFS) no more than 14 months. Herein, we present a case of a NSCLC patient with BM and METex14, who achieved prolonged PFS of 41 months following brain radiotherapy initiation and camrelizumab (a PD-1 inhibitor).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 75-year-old man was diagnosed with lung adenocarcinoma with BM and METex14. He received 7 months of crizotinib as first-line therapy, after that, the lung and brain lesions enlarged. Then, programmed cell death-ligand 1 (PD-L1) showed the tumor proportion score (TPS) approximately 80%, he underwent brain radiotherapy combined with camrelizumab immunotherapy. After treatment, the lesions in the patient\u2019s lung and brain were significantly reduced. Camrelizumab maintenance therapy was continued for 20 months until the appearance of pulmonary aspergillosis, with the patient achieving a PFS of 41 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of brain radiotherapy and camrelizumab demonstrated efficacy in a lung adenocarcinoma patient with BM and METex14. These findings suggest that immunotherapy may represent a potential treatment approach for high PD-L1 expression of METex14 NSCLC patients, warranting further investigation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1719029","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T06:30:38Z","timestamp":1770100238000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Durable disease stability in a patient with MET exon 14 skipping mutation and brain metastasis NSCLC following radiotherapy and immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Ji","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Oncology, Lung Cancer Center, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, People\u2019s Hospital of Boxing","place":["Binzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, People\u2019s Hospital of Boxing","place":["Binzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfang","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lung Cancer Center, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute","place":["Jinan, China"]},{"name":"Cheeloo College of Medicine, Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lung Cancer Center, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41419-017-0063-y","article-title":"Cell death-based treatment of lung adenocarcinoma","volume":"9","author":"Denisenko","year":"2018","journal-title":"Cell Death Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihimaki","year":"2014","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.01.007","article-title":"Non-small-cell lung cancer with brain metastasis at presentation","volume":"19","author":"Waqar","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00520-1","article-title":"Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC","volume":"18","author":"Grant","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.02.004","article-title":"First-line camrelizumab versus placebo plus chemotherapy with or without radiotherapy for brain metastases in NSCLC: the CTONG 2003 randomized placebo-controlled trial","volume":"20","author":"Li","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00211-X","article-title":"Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study","volume":"12","author":"Yu","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B14","doi-asserted-by":"crossref","first-page":"106214","DOI":"10.1016\/j.intimp.2020.106214","article-title":"Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis","volume":"80","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B15","first-page":"100675","article-title":"Three-year overall survival outcomes and correlative analyses in patients with NSCLC and high (50%-89%) versus very high (>\/=90%) programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab","volume":"5","author":"Ricciuti","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-1735","article-title":"First-line MET tyrosine kinase inhibitors versus immunotherapy \u00b1 chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC","volume":"31","author":"Pecci","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-023-01602-z","article-title":"The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review","volume":"128","author":"Nardone","year":"2023","journal-title":"Radiol Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"107322","DOI":"10.1016\/j.lungcan.2023.107322","article-title":"Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases","volume":"184","author":"Yan","year":"2023","journal-title":"Lung Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9025","article-title":"A comparative analysis of survival in patients with non-small cell lung cancer with brain metastases receiving intracranial radiation with and without immunotherapy","volume":"37","author":"Patruni","year":"2019","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/fon-2023-1061","article-title":"Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study","author":"Lu","year":"2024","journal-title":"Future Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31120598","article-title":"Metabolic complete response of metastatic oncogene-negative, PDL1-negative non-small cell lung cancer after chemo-immunotherapy and radiotherapy: A case report","volume":"31","author":"Surgo","year":"2024","journal-title":"Curr Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6277","article-title":"Immunotherapy or chemoimmunotherapy in older adults with advanced non-small cell lung cancer","volume":"10","author":"Tsukita","year":"2024","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e00289","DOI":"10.1002\/rcr2.v6.2","article-title":"Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab","volume":"6","author":"Uchida","year":"2018","journal-title":"Respirol Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1719029\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:30:42Z","timestamp":1771925442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1719029\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1719029"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1719029","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1719029"}}